Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe (N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554)

Biochemical Pharmacology

Volumn 54, Issue 11, 1997, Pages 1217-1224

  Aboagye, Eric O ^a,c   Lewis, Alexander D ^a,d   Tracy, Michael ^b   Workman, Paul ^a,e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SRI INTERNATIONAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HERIOT WATT UNIVERSITY   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

2 Nitroimidazoles; Hypoxia; Microsomes; NADPH:cytochrome P450 reductase; Reductive metabolism; SR 4554

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR PROBES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROIMIDAZOLES; OXIDATION-REDUCTION; OXYGEN; RATS;

EID: 0030723054     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00344-4     Document Type: Article

References (37)

1. Workman P and Stratford IJ, The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82, 1993.
2. Overgaard J, Sensitization of hypoxic cells - Clinical experience. Int J Radiat Biol 56: 801-811, 1989.
3. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C and Chapman JD, Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. Br J Cancer 74: S209-S212, 1996.
4. Groshar D, McEwan AJB, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI and Chapman JD, Imaging tumour hypoxia and tumour perfusion. J Nucleic Med 34: 885-888, 1993.
5. Koh W-J, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA and Griffin TW, Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22: 199-212, 1992.
6. Raleigh JA, Franko AJ, Treiber EO, Lunt JA and Allen PS, Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: Detection by F-19 nuclear magnetic resonance at 2.35 T. Int J Radiat Oncol Biol Phys 12: 1243-1245, 1986.
7. 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 16: 925-929, 1989.
8. Josephy PD, Palcic B and Skarsgard LD, In vitro metabolism of misonidazole. Br J Cancer 43: 443-450, 1981.
9. Chapman JD, Lee J and Meeker BE, Adduct formation by 2-nitroimidazole drugs in mammalian cells: Optimization of markers for tissue oxygenation. In: Selective Activation of Drugs by Redox Processes (Eds. Adams GE, Breccia A, Fielden EM and Wardman P), Vol. 198, pp. 313-323. Plenum Press, New York, 1990.
10. Franko AJ, Misonidazole and other hypoxia markers: Metabolism and applications. Int J Radiat Oncol Biol Phys 12: 1195-1202, 1986.
11. Workman P, Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 22: 631-637, 1992.
12. Walton MI and Workman P, Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 36: 887-896, 1987.
13. Joseph P, Jaiswal AK, Stobbe CC and Chapman JD, The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int J Radiat Oncol Biol Phys 29: 351-355, 1994.
14. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431, 1994.
15. Prekeges JL, Rasey JS, Grunbaum Z and Krohn KH, Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 42: 2387-2395, 1991.
16. McManus ME, Lang MA, Stuart K and Strong J, Activation of mixonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase. Biochem Pharmacol 31: 547-552, 1982.
17. Aboagye EO, Lewis AD, Johnson A, Workman P, Tracy M and Huxham IM, The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: Reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Br J Cancer 72: 312-318, 1995.
18. McCoy CL, McIntyre DJO, Robinson SP, Aboagye EO and Griffiths JR, Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. Br J Cancer 74: S226-S231, 1996.
19. Aboagye EO, Lewis AD, Graham MA, Tracy M, Kelson AB, Ryan KJ and Workman P, The pharmacokinetics, bioavailability, and biodistribution of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Des 11: 231-242, 1996.
20. Aboagye EO, Graham MA, Lewis AD, Workman P, Kelson AB and Tracy M, Development and validation of a solid phase extraction and high performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma. J Chromatogr B B672: 125-132, 1995.
21. Smith GC, Tew DG and Wolf CR, Distinction of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci USA 91: 8710-8714, 1994.
22. Twentyman PR, Brown MJ, Gray JW, Franko AJ, Scoles MA and Kallman RF, A new mouse tumour model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64: 595-604, 1980.
23. Olive PL and Durand RE, Misonidazole binding in SCCVII tumours in relation to the tumour blood supply. Int J Radiat Oncol Biol Phys 16: 755-761, 1989.
24. Van Putten LM and Kallman RF, Oxygenation status of a transplantable tumour during fractionated radiation therapy. J Natl Cancer Inst 40: 441-451, 1968.
25. Workman P, Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer 40: 335-353, 1979.
26. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. 1. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
27. Spector T, Refinement of the Coomassie blue method of protein quantitation. A simple and linear spectrophotometric assay for ≤0.5 to 50 μg of protein. Anal Biochem 86: 142-146, 1978.
28. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239: 2379-2385, 1964.
29. Woods JS, Fowler BA and Eaton DL, Studies on the mechanisms of thallium-mediated inhibition of hepatic mixed function oxidase activity. Correlation with inhibition of NADPH-cytochrome c (P450) reductase. Biochem Pharmacol 33: 571-576, 1984.
30. Franko AJ, Koch CJ, Garrecht BM, Sharplin J and Hughes D, Oxygen dependence of binding of mixonidazole to rodent and human tumour in vitro. Cancer Res 47: 5367-5376, 1987.
31. Koch CJ, The reduction activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In: Selective Activation of Drugs by Redox Processes (Eds. Adams GE, Breccia A, Fielden EM and Wardman P), Vol. 198, pp. 237-247. Plenum Press, New York, 1990.
32. Lord EM, Harwell L and Koch CJ, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53: 5721-5726, 1993.
33. Heimbrook DC and Sartorelli AC, Biochemistry of misonidazole reduction by NADPH-cytochrome c (P-450) reductase. Mol Pharmacol 29: 168-172, 1986.
34. Wardman P and Clarke ED, Oxygen inhibition of nitroreductase: Electron transfer from nitro radical-anions to oxygen. Biochem Biophys Res Commun 69: 942-949, 1976.
35. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD, Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: Correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 88: 259-269, 1996.
36. Aboagye EO, Fluorinated 2-nitroimidazoles: Non-invasive probes for detecting therapeutically relevant tumour hypoxia by magnetic resonance spectroscopy. Ph.D. Thesis, University of Glasgow, 1995.
37. Miller GG, Ngan-Lee J and Chapman JD, Intracellular